Skip to main content

  • FDA advisory panel to make recommendations on paclitaxel devices in peripheral arteries

    FDA advisory panel to make recommendations on paclitaxel devices in peripheral arteries

  • FDA advisory panel to make recommendations on paclitaxel devices in peripheral arteries

    A U.S. Food and Drug Administration (FDA) advisory panel will discuss recent observations of increased long-term mortality in peripheral arterial disease (PAD) patients treated with paclitaxel-coated balloons and paclitaxel-eluting stents during a two-day meeting in June.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details